-
F656892-1mlFanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC 50 s of 1.57 and 308 nM for tg DHFR ( Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis.In VitroFanotaprim
-
F288256-100mgGLUT1/GLUT4 inhibitor: also Fas-sensitizer.
-
F288256-10mgGLUT1/GLUT4 inhibitor: also Fas-sensitizer.
-
F288256-1mgGLUT1/GLUT4 inhibitor: also Fas-sensitizer.
-
F288256-25mgGLUT1/GLUT4 inhibitor: also Fas-sensitizer.
-
F288256-50mgGLUT1/GLUT4 inhibitor: also Fas-sensitizer.
-
F288256-5mgGLUT1/GLUT4 inhibitor: also Fas-sensitizer.
-
F650528-100mgFASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.Form:Solid.
-
F650528-10mgFASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.Form:Solid.
-
F650528-50mgFASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.Form:Solid.
-
F650528-5mgFASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.Form:Solid.
-
F656302-1mlFASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.